Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A ; day:22 ; month:12 ; year:2016 ; pages:1-11
Clinical pharmacokinetics ; (22.12.2016), 1-11
- Keyword
-
Biopharmazie
Pharmakodynamik
Pharmakokinetik
- Creator
-
Shah, Anita
- Contributor
-
Solms, Alexander
Garmann, Dirk
Katterle, Yvonne
Avramova, Verzhiniya
Simeonov, Stanislav
Lissitchkov, Toshko
SpringerLink (Online service)
- DOI
-
10.1007/s40262-016-0492-2
- URN
-
urn:nbn:de:1111-201701208076
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:43 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shah, Anita
- Solms, Alexander
- Garmann, Dirk
- Katterle, Yvonne
- Avramova, Verzhiniya
- Simeonov, Stanislav
- Lissitchkov, Toshko
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetics of Human Factor IX in a dog with Severe Hemophilia B.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Investigating clinical pharmacokinetics of brivaracetam by using a pharmacokinetic modeling approach
Pharmacokinetics of Human Factor IX in a dog with Severe Hemophilia B.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Investigating clinical pharmacokinetics of brivaracetam by using a pharmacokinetic modeling approach
Pharmacokinetics of Human Factor IX in a dog with Severe Hemophilia B.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B